Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

Lawrence F Eichenfield; Lawrence F Eichenfield; Wendy McFalda; Bradford Brabec; Elaine Siegfried; Pearl Kwong; Mark McBride; Jayson Rieger; Cynthia Willson; Matthew Davidson; Patrick Burnett

doi:10.1001/JAMADERMATOL.2020.3238

Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

Lawrence F Eichenfield
, Lawrence F Eichenfield
, Wendy McFalda
, Bradford Brabec
, Elaine Siegfried
, Pearl Kwong
, Mark McBride
, Jayson Rieger
, Cynthia Willson
, Matthew Davidson
, Patrick Burnett

University of California, San Diego
Boston Children's Hospital
Clarkston Skin Research, Clarkston, Michigan.
Midwest Children's Health Research Institute, Lincoln, Nebraska.
Saint Louis University
Solutions Through Advanced Research, Jacksonville, Florida.
Instat Consulting, Inc, Chatham, New Jersey.
Verrica Pharmaceuticals Inc, West Chester, Pennsylvania.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	JAMA Dermatology
Volume	156
Issue number	12
DOIs	https://doi.org/10.1001/JAMADERMATOL.2020.3238
State	Published - Dec 1 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1001/JAMADERMATOL.2020.3238License: Unspecified

Cite this

Eichenfield, L. F., Eichenfield, L. F., McFalda, W., Brabec, B., Siegfried, E., Kwong, P., McBride, M., Rieger, J., Willson, C., Davidson, M., & Burnett, P. (2020). Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatology, 156(12). https://doi.org/10.1001/JAMADERMATOL.2020.3238

Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. / Eichenfield, Lawrence F; Eichenfield, Lawrence F; McFalda, Wendy et al.
In: JAMA Dermatology, Vol. 156, No. 12, 01.12.2020.

Research output: Contribution to journal › Article › peer-review

Eichenfield, LF, Eichenfield, LF, McFalda, W, Brabec, B, Siegfried, E, Kwong, P, McBride, M, Rieger, J, Willson, C, Davidson, M & Burnett, P 2020, 'Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.', JAMA Dermatology, vol. 156, no. 12. https://doi.org/10.1001/JAMADERMATOL.2020.3238

@article{c78f7dce6b6b4d63a96cc97c83330f22,

title = "Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7\% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.",

author = "Eichenfield, \{Lawrence F\} and Eichenfield, \{Lawrence F\} and Wendy McFalda and Bradford Brabec and Elaine Siegfried and Pearl Kwong and Mark McBride and Jayson Rieger and Cynthia Willson and Matthew Davidson and Patrick Burnett",

note = "Informaci{\'o}n del art{\'i}culo Safety and efficacy of vp-102, a proprietary, drug-device combination product containing cantharidin, 0.7\% (w/v), in children and adults with molluscum contagiosumtwo phase 3 randomized clinical trials",

year = "2020",

month = dec,

day = "1",

doi = "10.1001/JAMADERMATOL.2020.3238",

language = "American English",

volume = "156",

journal = "JAMA Dermatology",

issn = "2168-6084",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

AU - Eichenfield, Lawrence F

AU - McFalda, Wendy

AU - Brabec, Bradford

AU - Siegfried, Elaine

AU - Kwong, Pearl

AU - McBride, Mark

AU - Rieger, Jayson

AU - Willson, Cynthia

AU - Davidson, Matthew

AU - Burnett, Patrick

N1 - Información del artículo Safety and efficacy of vp-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosumtwo phase 3 randomized clinical trials

PY - 2020/12/1

Y1 - 2020/12/1

UR - https://dialnet.unirioja.es/servlet/articulo?codigo=7713209

U2 - 10.1001/JAMADERMATOL.2020.3238

DO - 10.1001/JAMADERMATOL.2020.3238

M3 - Article

SN - 2168-6084

VL - 156

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 12

ER -

Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

Disciplines

Access to Document

Other files and links

Cite this